Dianthus Therapeutics Past Earnings Performance
Past criteria checks 0/6
Dianthus Therapeutics's earnings have been declining at an average annual rate of -45.7%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 10.5% per year.
Key information
-45.7%
Earnings growth rate
57.8%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 10.5% |
| Return on equity | -19.9% |
| Net Margin | -1,250.3% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Dianthus Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 5 | -67 | 23 | 65 |
| 30 Jun 24 | 4 | -57 | 25 | 48 |
| 31 Mar 24 | 3 | -50 | 21 | 40 |
| 31 Dec 23 | 3 | -44 | 18 | 33 |
| 30 Sep 23 | 4 | -43 | 16 | 34 |
| 30 Jun 23 | 4 | -36 | 9 | 33 |
| 31 Mar 23 | 6 | -31 | 8 | 30 |
| 31 Dec 22 | 6 | -28 | 7 | 29 |
| 31 Dec 21 | 1 | -13 | 2 | 13 |
Quality Earnings: 87E is currently unprofitable.
Growing Profit Margin: 87E is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 87E's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare 87E's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 87E is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: 87E has a negative Return on Equity (-19.86%), as it is currently unprofitable.